Experimental treatment with sodium stibogluconate of hamsters infected with Leishmania (Leishmania) chagasi and Leishmania (Leishmania) amazonensis

Tratamento experimental com stibogluconato de sódio em hamsters infectados com Leishmania (Leishmania) chagasi e Leishmania (Leishmania) amazonensis

Elizabeth M. de Figueiredo, Jaime Costa e Silva and Reginaldo P. Brazil

Abstract  The present paper reports the experimental treatment of hamsters infected with Leishmania chagasi and Leishmania amazonensis with sodium stibogluconate (20mg/kg/day x 20 days). Only with L. chagasi did the treatment result in the complete elimination of parasites from the spleen. However, no parasitological cure was achieved in hamsters infected with L. amazonensis.

Key-words: Leishmania. Sodium stibogluconate. Treatment.

Resumo  O presente trabalho é um relato do tratamento experimental de hamsters infectado com Leishmania chagasi e Leishmania amazonensis com o stibogluconato de sódio (20mg/kg/dia x 20 dias). Somente na infecção com L. chagasi, o tratamento resultou em completa eliminação dos parasitos do baço. Entretanto, não houve cura parasitológica em hamsters infectados com L. amazonensis.


Leishmaniases are diseases caused by several species of Leishmania (Ross, 1903) and both visceral and cutaneous leishmaniasis are regarded by the World Health Organization (WHO) as two of most important health problems in the world. Pentavalent antimonials are currently used in the treatment of both clinical forms. They are available as meglumine antimoniate, which is generally referred to as glucantime (Rhône Poulenc, Paris, France) and is used in Latin America and French-speaking countries. Sodium stibogluconate referred to as Pentostan (Wellcome Foundation, London, UK), is used in English-speaking countries. In 1982, the World Health Organization (TDR/CHEM/LEISH/HL, 1982) recommended a regimen of 20mg/kg/day of pentavalent antimonial for treating leishmaniasis instead of 10mg/kg/day as previously recommended1. In this preliminary report, we evaluate the action of sodium stibogluconate produced by Shandong Xinhua Pharmaceutical Factory, China, which is now available in Brazil through the Ministry of Health (FNS) for the treatment of cutaneous and visceral leishmaniasis as a substitute for meglumine antimoniate (Glucantime®). Males of outbred hamsters (Mesocricetus auratus), weighing 90-110g were infected with the reference strains: Leishmania (L.) chagasi (MHOM/BR/74/PP75) isolated from a case of visceral leishmaniasis in Ituaçu, Bahia State, Brazil and Leishmania (L.) amazonensis (IFLA/BR67/PH8) isolated from Lutzomyia...
flaviscutellata in Utinga, Pará State, Brazil. In the first group, 20 hamsters were inoculated intraperitoneally with 0.1ml of phosphate-buffered saline containing $10^7$ amastigotes of *L. chagasi* obtained from a spleen suspension of previously infected hamsters. In the second group, 20 hamsters were inoculated subcutaneously in the nose with 0.1ml of phosphate-buffered saline containing $10^7$ amastigotes of *L. amazonensis* from a suspension of nose tissue from a previously inoculated hamster. Sodium stibogluconate was administered to hamsters ten days after infection with the recommended dose of 20mg/kg/day for 20 days by intramuscular (im) injection. Therapeutic activity in hamsters infected with *L. chagasi* was estimated 19 days after the end of the treatment by comparison with a control group. Spleens were weighed and measured at the end of the experiment and the number of parasites was determined in the spleen of each animal by counting 100 nuclei of cells in the imprint stained by Giemsa. For *L. amazonensis* infection, the development of the lesion was followed weekly for nine weeks by measuring the noses of treated and control hamsters with a caliper. Thirty days after the end of treatment the animals were killed and the number of amastigotes was determined in the imprint of the lesion. The results were compared with control groups using analysis of variance in the Minitab program. Sodium stibogluconate was effective against *L. chagasi* infection with complete clearance of amastigotes in the spleen of the treated group. In control animals, parasites were present ($x = 9.1 \pm 6.2$ amastigotes/100 cells). No significant difference was detected in the weight ($0.05 < p = 0.506$), length ($0.05 < p = 0.153$) or width ($0.05 < p = 0.113$) of the spleens of treated animals when compared with controls. This could be explained by the low parasitism of the spleen at the end of the experiment which was not enough to show any clinical alteration of the organ.

Despite a slight clinical improvement (Figure 1), amastigote clearance was not achieved with the recommended dose of 20mg/kg/day in the treatment of cutaneous leishmaniasis caused by *L. amazonensis*, as demonstrated by the presence of large numbers of amastigotes in the treated group at the end of the experiment. This result has important implications since this drug is now being distributed by the Health Authorities (FNS) for the treatment of both visceral and cutaneous leishmaniasis in Brazil even though there was no previous experimental evaluation of this drug against any Brazilian species of *Leishmania*. 

![Figure 1 - Clinical evaluation of hamsters infected with Leishmania (L.) amazonensis and treated with sodium stibogluconate.](image-url)
REFERENCES
